AC Immune gets $4m Goradia grant to extend Parkinson's vaccine trial
AC Immune SA has secured a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to extend the first part of its ongoing Phase 2 VacSYn trial of ACI-7104, an active immunotherapy targeting alpha-synuclein in early Parkinson's disease. The extension will gather an additional two years of safety and efficacy data, with final results from the original Part 1 cohort (to week 104) expected in the second half of 2026.
ACI-7104.056 is designed to stimulate a targeted antibody response against pathological oligomeric alpha-synuclein, the misfolded protein thought to drive the spread of neurodegeneration in Parkinson's disease. Interim data reported in December 2025 showed a favourable safety profile, robust and boostable antibody responses, evidence of target engagement, and what the company described as encouraging clinical signals. The company says the results are consistent with a potential disease-modifying effect, though it has not yet disclosed full efficacy data or a quantified measure of clinical benefit.
Trial context
Martin Zugel, interim chief executive designate and chair of the board at AC Immune, said the grant would "significantly impact" the Part 1 extension and enable the generation of "vital long-term data." The company's permanent chief executive, Andrea Pfeifer, described ACI-7104 as showing "considerable promise in clinical testing," language the company has softened from earlier descriptions of its potential.
The Goradia Foundation has a history of supporting translational research, having previously made substantial grants to the University of Texas MD Anderson Cancer Center. The involvement of a private philanthropic funder in a NASDAQ-listed company's clinical programme is notable; such non-dilutive capital is increasingly sought by mid-stage biotechs managing cash runway alongside shareholder expectations.
Competitive landscape and regulatory read-across
The alpha-synuclein space has attracted sustained attention over the past decade, with a range of passive and active immunotherapy approaches from companies including Prothena and Roche, as well as several academic spinouts. Progress has been uneven: a number of earlier-generation anti-alpha-synuclein antibodies failed to demonstrate clinical benefit in Phase 2, making long-term safety and robust biomarker data increasingly important for differentiation. AC Immune's active immunotherapy approach, which recruits the patient's own immune system rather than delivering exogenous antibodies, has a distinct mechanism and a potentially more durable dosing profile, though direct head-to-head comparisons are not yet available.
Regulatory interest in disease-modification endpoints for Parkinson's disease has grown following the FDA's engagement with the Alzheimer's field on surrogate biomarker endpoints. While no equivalent accelerated approval pathway has yet been established for Parkinson's, the two-year extension data generated through this grant could be directly relevant to discussions with regulators about what constitutes acceptable evidence of slowing progression. The company has stated its ambition to pursue precision prevention rather than symptomatic treatment, a framing that aligns with emerging regulatory thinking but will require robust longitudinal data to support.
AC Immune's pipeline also spans Alzheimer's disease and NeuroOrphan indications, and the company has cited more than $4.5 billion in potential milestone payments from its existing partnership portfolio. The $4 million Goradia grant is modest relative to typical Phase 2 operating costs, but its value lies primarily in extending the dataset without equity dilution at a stage when investors are closely monitoring the company's cash position ahead of the H2 2026 data readout.